Sanofi stops development of Nurix-partnered immune drug
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.